An open clinical trial of risperidone monotherapy in young children with autistic disorder

Psychopharmacology Bulletin

Volumn 33, Issue 1, 1997, Pages 155-159

  Findling, Robert L ^a,c   Maxwell, Kathleen ^b   Wiznitzer, Max ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Department of Psychiatry ^*  (United States)

Author keywords

autistic disorder; children; medication; risperidone; treatment

Indexed keywords

CLOMIPRAMINE; CLONIDINE; FLUOXETINE; HALOPERIDOL; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RISPERIDONE; SERTRALINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPULSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; INFANTILE AUTISM; MALE; OBESITY; OBSESSION; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOMETRY; RATING SCALE; SCHIZOPHRENIA; SEDATION; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; HUMANS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE;

EID: 0030966387     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Allen, L, and Tejera, C. Treatment of clozapine-induced obsessive-compulsive symptoms with sertraline. Am. J. Psychiatry 151:1096-1097, 1994.
2. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: The Association, 1994.
3. Anderson, LT; Campbell, M; Grega, DM; Perry, R; Small, AM; and Green, WH. Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am. J. Psychiatry 141:1195-1202, 1984.
4. Campbell, M, and Palij, M. Behavioral and cognitive measures used in psychopharmacologic studies of infantile autism. Psychopharmacol. Bull. 21:1047-1053, 1985a.
5. Campbell, M, and Palij, M. Measurement of side effects including tardive dyskinesia. Psychopharmacol. Bull. 21:1063-1082, 1985b.
6. Carlsson, A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am. J. Psychiatry 135:164-173, 1978.
7. Casaer, P; Walleghem, D; Vandenbussche, I; Huang, M-L; and De Smedt, G. Pharmacokinetics and safety of risperidone in autistic children. Ped. Neurology 11:89, 1994.
8. Chouinard, G; Jones, B; Remington, G; Bloom, D; Addington, D; MacEwan, GW; Labelle, A; Beauclair, L; and Arnott, W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13:25-40, 1993.
9. Claus, A; Bollen, J; De Cuyper, H; Eneman, M; Malfroid, M; Peuskens, J; and Heylen, S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study. Acta Psychiatr. Scand. 85:295-305, 1992.
10. Cohen, SA, and Underwood, MT. The use of clozapine in a mentally retarded and aggressive population. J. Clin. Psychiatry 55:440-444, 1994.
11. Cook, EH; Rowlett, R; Jaselskis, C; and Leventhal, BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J. Am. Acad. Child Adolesc. Psychiatry 31:739-735, 1992.
12. Engelhardt, DM; Polizos, P; Waizer, J; and Hoffman, SP. A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children. J. Aut. Child Schizophr. 3:128-137, 1973.
13. Ernst, M; Magee, HJ; Locascio, JJ; Rosenberg, CR; and Campbell, M. Pimozide in autistic children. Psychopharmacol. Bull. 28:187-191, 1992.
14. Fish, B. Children's Psychiatric Rating Scale (Scoring). Psychopharmacol. Bull. 21:753-770, 1985.
15. Gillberg, C. The treatment of epilepsy in autism. J. Aut. Dev. Dis. 21:61-77, 1991.
16. Gordon, CT; State, RC; Nelson, JE; Hamburger, SD; and Rapoport, JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch. Gen. Psychiatry 50:441-447, 1993.
17. Horrigan, JP, and Barnhill, LJ. "Risperidone and Explosive, Aggressive Autism." Poster presented at the 42nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New Orleans, LA, October 1995.
18. Insel, TR; Murphy, DL; Cohen, RM; Alterman, L; Kilts, C; and Linnoila, M. Obsessive-compulsive disorder: A double-blind trial of clomipramine and clorgyline. Arch. Gen. Psychiatry 40:605-612, 1983.
19. 2 antagonistic properties. J. Pharmacol. Exp. Ther. 244:685-693, 1988.
20. Keepers, GA; Clappison, VJ; and Casey, DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch. Gen. Psychiatry 40:1113-1117, 1983.
21. Kerwin, RW. The new atypical antipsychotics: A lack of extrapyramidal side effects and new routes in schizophrenia research. Br. J. Psychiatry, 164:141-148, 1994.
22. Kopala, L, and Honer, WG. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia. Am. J. Psychiatry 151:1714-1715, 1994.
23. Leysen, JE; Janssen, PMF; Gommeren, W; Wynants, J; Pauwels, PJ; and Janssen, PAJ. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol. Pharmacol. 41:494-508, 1992.
24. Marder, SR, and Meibach, RC. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 151:825-835, 1994.
25. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J. Pharmacol. Exp. Ther. 265:498-508, 1993.
26. McDougle, CJ; Brodkin, ES; Yeung, PP; Naylor, ST; Cohen, DJ; and Price, LH. Risperidone in adults with autism or pervasive developmental disorder. J. Child Adolesc. Psychopharmacol. 5:273-282, 1995.
27. Megens, AAHP; Awouters, FHL; Schotte, A; Meert, TF; Dugovic, C; Niemegeers, CJE; and Leysen, JE. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 114:9-23, 1994.
28. National Institute of Mental Health. Clinical Global Impressions (CGI) scale. Psychopharmacol. Bull. 21:839-843, 1985.
29. Overall, JE, and Campbell, M. Behavioral assessment of psychopathology in children: Infantile autism. J. Clin. Psychol. 144:708-716, 1988.
30. Patil, VJ. Development of transient obsessive-compulsive symptoms during treatment with clozapine. Am. J. Psychiatry 149:272, 1992.
31. Peroutka, SJ, and Snyder, SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am. J. Psychiatry 137:1518-1522, 1980.
32. Perry, R; Campbell, M; Adams, P; Lynch, N; Spencer, EK; Curren, EL; and Overall, JE. Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration. J. Am. Acad. Child Adolesc. Psychiatry 28:87-92, 1989.
33. Purdon, SE; Lit, W; Labelle, A; and Jones, BDW. Risperidone in the treatment of pervasive developmental disorder. Can. J. Psychiatry 39:400-405, 1994.
34. Remington, G, and Adams, M. Risperidone and obsessive-compulsive symptoms. J. Clin. Psychopharmacol. 14:358-359, 1994.
35. Richardson, MA; Haugland, G; and Craig, TJ. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia and associated factors in child and adolescent psychiatric patients. Am. J. Psychiatry 148:1322-1328, 1991.
36. Schopler, E; Reichler, R; DeViellis, R; and Daly, K. Towards objective classification of childhood autism: Childhood autism rating scale (CARS). J. Aut. Dev. Dis. 10:91-103, 1980.
37. Snyder, SH. Dopamine receptors, neuroleptics, and schizophrenia. Am. J. Psychiatry 138:460-464, 1981.
38. Vanden Borre, R; Vermote, R; Buttiens, M; Thiry, P; Dierick, G; Geutjens, J; Sieben, G; and Heylen, S. Risperidone as add-on therapy in behavioral disturbances in mental retardation: A double-blind placebo-controlled cross-over study. Acta Psychiatr. Scand. 87:167-171, 1993.
39. Volkmar, FR, and Nelson, DS. Seizure disorders in autism. J. Am. Acad. Child Adolesc. Psychiatry 29:127-129, 1990.